Combination of a PD-1 antagonist and a RAF inhibitor for treating cancer

A method for the treatment of lung cancer or colorectal cancer in a subject, comprising administering to the subject in need thereof a therapeutically effective amount of a PD-1 antagonist in combination with a therapeutically effective amount of a RAF inhibitor,

• wherein the PD-1 antagonist is an antibody or an antigen binding fragment thereof, which specifically binds to human PD-1 and which comprises a heavy chain variable region (Vh) and a light chain variable region (Vk), wherein the Vh comprises complimentary determining region (CDR) 1, CDR2, and CDR3 comprising SEQ ID NOs:
• 31, 32, and 33, respectively;
• and the Vk comprises CDR1, CDR2, and CDR3 comprising SEQ ID NOs:
• 34, 35, and 36, respectively;
• and
• wherein the RAF inhibitor is a compound of Formula (II),
• or a pharmaceutically acceptable salt thereof.